|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||56.6800 - 56.9300|
|52 Week Range||53.8300 - 64.6500|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
Johnson & Johnson (JNJ) surpassed EPS (earnings per share) and revenue estimates in 1Q18. For 1Q18, Johnson & Johnson reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against the estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q18.
GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.
Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.
Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex. The company classifies its business portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
On January 29, 2018, Sanofi (SNY) announced its acquisition of Ablynx (ABLX), a Belgium-based biopharmaceutical company, for 45 euros per Ablynx share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash. As per the agreement, Sanofi will acquire all outstanding Ablynx ordinary shares, including American depositary shares, warrants, and convertible bonds. The deal was unanimously approved by the boards of directors of both Sanofi and Ablynx.
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.1 billion pounds from the sale of its human immunodeficiency virus (or HIV) products, which is year-over-year (or YoY) growth of 16% on a reported basis and 13% on a constant exchange rate (or CER). The company witnessed sales worth 681 million pounds for its HIV franchise in the US market in 3Q17, which is YoY growth of 21% on a reported basis and 18% on CER basis.